Lilly Acquires Engage Bio for Up to $202 Million to Build Non-Viral DNA Delivery Platform

Overview

Eli Lilly agreed on May 20, 2026 to acquire Engage Bio, a preclinical San Carlos, California-based startup, for up to $202 million in cash, according to BioPharma Dive and Pharmaceutical Executive. The deal gives Lilly access to Engage’s Tethosome platform, a non-viral DNA delivery system designed to solve two persistent obstacles in the field: getting therapeutic DNA into cell nuclei reliably, and doing so without triggering the immune responses that prevent viral gene therapies from being redosed.

What We Know

The transaction is structured as an upfront cash payment plus additional milestone payments based on development and commercialization achievements, with the total potential value reaching $202 million, BioPharma Dive reported. Cooley LLP represented Engage Bio in the deal, Pharmaceutical Executive noted.

Engage, founded in 2021 and backed by SciFounders, Pioneer Fund, Cal Innovation Fund, Y Combinator, and the Cystic Fibrosis Foundation, also received non-dilutive grants from the Gates Foundation and NIH-NCATS, according to Life Science History.

The Tethosome Platform

The core technology pairs DNA with lipid nanoparticles — the same fatty delivery shells used in mRNA COVID-19 vaccines — but adds a second component that sets it apart. Pharmaceutical Executive described the mechanism as a DNA expression vector carrying the therapeutic transgene combined with mRNA encoding a proprietary DNA-binding protein. Once the lipid nanoparticle delivers its cargo and the mRNA is translated inside the cell, the DNA-binding protein then binds to the expression vector and shuttles it into the nucleus while evading innate immune sensors, according to Pharmaceutical Executive. The result, BioPharma Dive reported, is that the platform uses a messenger RNA sequence for a protein that can directly transport the material to the cell’s nucleus.

The approach is designed to achieve sustained gene expression without significant DNA integration, distinguishing it from both viral vectors and earlier non-viral delivery systems, Pharmaceutical Executive reported.

Why Non-Viral Delivery Matters

The dominant approach to gene therapy today relies on adeno-associated viruses to ferry therapeutic DNA into cells. But as BioPharma Dive noted, AAVs come with safety risks, dosing constraints, manufacturing hurdles, and high costs. The redosing problem is particularly acute: because viruses are at odds with the immune system, a viral-based therapy is a one-time treatment because another dose would be rendered ineffective by antibodies the immune system produces in response to the first, according to BioPharma Dive.

Engage’s platform is designed to avoid this. Because the immune system does not view therapies from this technology as foreign, it does not mount an immune reaction, MedCity News reported. That could theoretically allow patients to receive multiple doses over time — a significant potential advantage for diseases where gene expression fades.

The company’s early preclinical work focused on liver-targeting applications, specifically hemophilia A and hepatocellular carcinoma models, according to Pharmaceutical Executive. However, Engage is still preclinical and has not disclosed specific disease targets for clinical development, MedCity News noted.

Lilly’s Expanding Genetic Medicine Portfolio

The Engage acquisition continues Lilly’s aggressive push into genetic medicines. Earlier in 2026, Lilly completed its acquisition of Orna Therapeutics in February for up to $2.4 billion and reached an agreement to acquire Kelonia Therapeutics in April for $3.25 billion upfront, MedCity News reported. The company has also previously signed a research collaboration with Profluent Bio worth up to $2.25 billion around AI-designed site-specific recombinases, as The Machine Herald previously reported.

What Executives Said

“We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine,” said Will Olsen, Engage’s co-founder and CEO, in a statement reported by Pharmaceutical Executive. “We believe that the combination of Engage’s platform with Lilly’s significant capabilities will meaningfully accelerate development of new genetic therapies.”

In a separate LinkedIn post, Olsen added: “In Lilly, we found a partner that is willing to take early and decisive bets on potentially transformative technologies,” according to MedCity News. He also noted: “With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines,” according to Life Science History.

What We Don’t Know

The upfront cash component of the deal was not disclosed by either company, nor were the specific milestones tied to the remaining payments. Engage has not announced which diseases it intends to target in clinical development, though its preclinical focus on liver conditions such as hemophilia A and hepatocellular carcinoma, per Pharmaceutical Executive, suggests where Lilly may direct initial efforts.

No clinical timelines were announced. Because Tethosome remains preclinical, its performance in humans — including whether the nuclear localization mechanism and immune evasion properties translate from animal models — remains to be demonstrated. The field of non-viral DNA delivery has historically faced a large gap between early efficiency gains in the lab and therapeutic potency in patients.